David Shaw’s AstraZeneca AZN Stock Holding History

David Shaw’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-7,450	Closed	-$1.14M	–	4590
2025 Q3	$1.14M	Buy	+7,450	New	+$1.13M	﹤0.01%	3378
2022 Q1	–	Sell	-44,520	Closed	-$5.19M	–	5520
2021 Q4	$5.19M	Hold	44,520	–	–	﹤0.01%	2334
2021 Q3	$5.35M	Hold	44,520	–	–	﹤0.01%	2054
2021 Q2	$5.33M	Buy	+44,520	New	+$4.88M	﹤0.01%	1974
2020 Q3	–	Sell	-32,100	Closed	-$3.4M	–	3833
2020 Q2	$3.4M	Hold	32,100	–	–	﹤0.01%	1978
2020 Q1	$2.87M	Hold	32,100	–	–	﹤0.01%	1893
2019 Q4	$3.2M	Buy	+32,100	New	+$3.02M	﹤0.01%	2096
2016 Q1	–	Sell	-71,000	Closed	-$4.82M	–	3412
2015 Q4	$4.82M	Hold	71,000	–	–	0.01%	1432
2015 Q3	$4.52M	Hold	71,000	–	–	0.01%	1476
2015 Q2	$4.52M	Sell	71,000 -30,000	-30%	-$2.05M	0.01%	1547
2015 Q1	$6.91M	Sell	101,000 -152,400	-60%	-$10.6M	0.01%	1177
2014 Q4	$17.8M	Buy	253,400 +30,000	+13%	+$2.15M	0.02%	765
2014 Q3	$16M	Hold	223,400	–	–	0.02%	813
2014 Q2	$16.6M	Buy	223,400 +35,100	+19%	+$2.54M	0.02%	801
2014 Q1	$12.2M	Buy	188,300 +174,700	+1,285%	+$11.3M	0.02%	924
2013 Q4	$807K	Hold	13,600	–	–	﹤0.01%	3351
2013 Q3	$706K	Hold	13,600	–	–	﹤0.01%	3336
2013 Q2	$643K	Buy	+13,600	New	+$693K	﹤0.01%	3058

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

David Shaw's AZN Position: Q2 2026 in Review

David Shaw increased its AstraZeneca (AZN) stake by 4,277% in Q2 2026, buying an estimated $201M and bringing the position to 1,094,593 shares worth $208M. The position accounts for 0.1% of the portfolio, ranked #214.

David Shaw first reported a position in AZN in Q2 2013 and has held it in 42 quarters since. The position peaked at $316M in Q4 2024. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

David Shaw held 1,094,593 shares of AstraZeneca worth $208M as of Q2 2026.
David Shaw bought 1,069,588 AstraZeneca shares in Q2 2026, an estimated $201M.
AstraZeneca made up 0.1% of David Shaw's portfolio in Q2 2026, its #214 holding.
David Shaw first reported a position in AstraZeneca in Q2 2013 and has held it in 42 quarters since.
David Shaw's AstraZeneca position peaked at $316M in Q4 2024.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.